Compare NEO & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | CIM |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2008 | N/A |
| Metric | NEO | CIM |
|---|---|---|
| Price | $7.90 | $13.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $11.14 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 2.0M | 830.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.63 | N/A |
| Revenue Next Year | $9.73 | $3.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $9.85 |
| 52 Week High | $13.74 | $14.88 |
| Indicator | NEO | CIM |
|---|---|---|
| Relative Strength Index (RSI) | 19.28 | 42.85 |
| Support Level | $7.07 | $12.93 |
| Resistance Level | $8.89 | $13.19 |
| Average True Range (ATR) | 0.47 | 0.30 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 2.30 | 0.49 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.